Hemorrhagic rectocolitis (UC) belongs to the family of chronic inflammatory bowel diseases (IBD). It is an inflammatory bowel disease affecting the rectum and sometimes all or part of the colon. This chronic disease evolves in relapses, alternating with phases of remission. The aim of maintenance therapy for UC is to maintain clinical and endoscopic remission, without corticosteroids. Clinical remission is defined as the absence of rectal bleeding and fewer than 4 bowel movements per 24 h. Endoscopic remission correlates with an overall improvement in the course of the disease. The absence of acute histological inflammation is predictive of disease remission.